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KetamineAbstract Aim and background: In this study we compared between sedative effect of dexmedeto-
midine and ketamine as regards their sedative, hemodynamic, respiratory effects and complication
when given as infusions in children undergoing magnetic resonance imaging (MRI).
Methods: One hundred and ten children of both sex aged 3–7 years were randomly distributed into
two groups. The ﬁrst group (n= 55) received dexmedetomidine (D) l lg/kg as a loading dose fol-
lowed by continuous infusion 0.5–0.75 lg/kg/h and the second group (n= 55) received ketamine
(K) 1 mg/kg as a loading dose followed by continuous infusion 10–15 lg/kg/min. Inadequate seda-
tion was deﬁned as difﬁculty in completing the procedure because of movement of the child during
MRI. The children who were inadequately sedated were given a single dose of propofol 0.5 mg/kg in
both groups intravenously (iv) as rescue doses. Mean arterial pressure (MAP), heart rate (HR),
peripheral oxygen saturation (SpO2) and respiratory rate (RR) were monitored during this study.
Results: Inadequate sedation was observed in 6 children from (D) group and 4 children from (K)
group during MRI examination. Onset of sedation was signiﬁcantly shorter in (K) group, but the
discharge time was longer in this group. MAP and HR decreased signiﬁcantly from baseline during
sedation in group (D). Nausea, vomiting, and dysphoria were observed in 3 children of group (K).
Conclusion: Dexmedetomidine provided adequate sedation in most of the children without hemo-
dynamic or respiratory embarrassment, in comparison with ketamine which provided adequate
sedation but with delayed discharge time and more side effects.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sedation of children for imaging procedures is often challeng-
ing. While not painful, these procedures require patient immo-
bility for as long as one to three hours. MRI examination is
very sensitive to motion artifacts. If any movement occurs
Table 1 Ramsay sedation assessment scale.
Awake levels Patient anxious or agitated or both 1
Patient cooperative, oriented and tranquil 2
Patient responds to commands only 3
Asleep levels A brisk response to a light glabellar tap 4
A sluggish response to a light glabellar tap 5
No response 6
264 A.M. Eldeek et al.during the imaging process for one sequence, the entire
sequence must be repeated [1]. Children may be frightened
by being in the magnetic resonance imaging (MRI) tunnel or
duct and the loud noise generated during the imaging process.
Thus sedation is required for children aged between 4 and
7 years. Children may not remain immobile for long enough
to allow a sequence to be completed [2].
Consequently, a deep level of sedation is required during
MRI. Deep sedation is deﬁned as ‘‘a medically induced state
of central nervous system depression in which the patient is
essentially unconscious, and so does not respond to verbal
command”. The potential complications of deep sedation
include hypoventilation, apnea, airway obstruction, aspira-
tion, hypotension, bradycardia, and increased intracranial
pressure [3].
If any complications occur during an MRI examination,
the nature of the set-up precludes easy access to the patient.
Also, limited access to the patient may pose a safety risk dur-
ing MRI examination [2,3]. There has been debate over the
appropriate drugs and dosage regimens for MRI sedation in
children.
Dexmedetomidine is a potent highly selective a
2-adrenoreceptor agonist with a distribution half-life of
approximately 8 min and a terminal half-life of 3.5 h [4].
Dexmedetomidine, as a sedative agent, can provide easily con-
trollable analgesia and sedation without respiratory depression
and has been widely used in the intensive care unit (ICU) for
sedation and postoperative analgesia [5].
Ketamine is an N-Methyl-D-Aspartate (NMDA) receptor
antagonist used clinically as an anesthetic, sedative, and anal-
gesic in pediatric patients.
In this preliminary study, the aim was to improve sedation
and develop a regimen based on dexmedetomidine, and to
evaluate the sedative, hemodynamic, respiratory effects and
incidence of complication of dexmedetomidine compared with
ketamine in children undergoing MRI examination in Ain
Shams University hospitals from January 2014 to August
2015.2. Methods
After departmental approval and written parents consent, 110
ASA (American Society of Anesthesiologists) I–II children
aged 3–7 years undergoing MRI were included in this random-
ized prospective study from January 2014 to August 2015.
Patients with heart, lung or neurological disease, central ner-
vous system or extremity trauma, or contraindication or
allergy to any of the drugs studied were excluded. Randomiza-
tion was done using a computer-generated random number list
in 1:1 ratio. The randomization list was concealed until the
time of randomization. Allocation of patients to either group
was done by a clinician not involved in the study and the ran-
domization codes were kept concealed until after data collec-
tion and analysis were completed. All children were allowed
to take clear liquids up to 2 h before sedation but food (includ-
ing milk) intake was withheld for at least 8 h in children older
than 3 years. To facilitate intravenous (i.v.) cannulation,
EMLA cream was applied on the dorsum of both hands l h
before transfer to the preparation room. Presedation behavior
was assessed on a four-point scale (l = calm, cooperative;
2 = anxious but reassurable; 3 = anxious and not reassurable;4 = crying or resisting). Categories 1 and 2 were classed as
stressed # unstressed and categories 3 and 4 as distressed.
Baseline values were recorded upon arrival in the preparation
room. A 22G (gauge/size) or 24G venous cannula was inserted
in the dorsum of the hand. Children were randomized using a
computer generated random numbers table into groups: D and
F; 55 patients each. Solutions of dexmedetomidine (Precedex,
Abbott laboratories, Lake Forest, IL60045, USA), l ml at a
concentration of 100 lg/ml, were diluted with 49 ml normal
saline to a concentration of 2 lg/ml, and ketamine (Ketamine
50, Sigma-Tec Pharmaceuticals Industries, Egypt-SAE), l ml at
a concentration of 50 mg/ml, was diluted with 49 ml normal
saline to a concentration of l mg/ml. A loading dose
(dexmedetomidine l lg/kg was given over 10 min or ketamine
1 mg/kg with glycopyrrolate 5 lg/kg) was given intravenously
followed by continuous infusion (dexmedetomidine 0.5–
0.75 lg/kg/h or ketamine 10–15 lg/kg/min). The sedation level
of the children was measured every 10 min using the Ramsay
sedation scale by evaluating response to sound, verbal com-
mands or tactile stimulation. The Ramsay scale (Table 1)
assigns a score of 1–6 based on the clinical assessment of the
level of sedation (1 = anxious, agitated, restless; 2 = awake,
but cooperative, tranquil, orientated; 3 = responds to verbal
commands only). Scores 4–6 apply to sleeping patients and
are graded according to the response to loud noise or a glabel-
lar tap (4 = brisk response; 5 = sluggish response; 6 = no
response). The children were taken into the MRI room after
a Ramsay score of 6 and hemodynamic and respiratory stabil-
ity were achieved. If a Ramsay score of 6 was not achieved
after 25 ± 5 min of study drug infusion or inadequate sedation
occurred during MRI examination, a single rescue dose of
propofol 0.5 mg/kg i.v. was administered to the patients in
both groups. Inadequate sedation was deﬁned as difﬁculty in
completing the procedure because of movement during MRI
examination.
Mean arterial pressure (MAP), heart rate (HR), peripheral
oxygen saturation (SpO2) and respiratory rate (RR) were mon-
itored continuously and recorded at 5-min intervals during the
study period. Spontaneous respiration was maintained in all
children, and oxygen via a facemask was given as 8 L/min to
maintain SpO2 above 95%.
The quality of the MRI examination was evaluated using a
three point scale (l = no motion; 2 = minor movement;
3 = major movement necessitating another scan). At the end
of the MRI, drug infusion was discontinued and the children
were transferred to the recovery room. The onset of sedation
time was deﬁned as the time from starting drug infusion to
achieving a Ramsay score of 6. Recovery time was the time
between discontinuation of drug infusion and reaching a
Ramsay score of 2. Discharge time was the time between dis-
continuation of drug infusion and discharge of the child from
Table 3 Results of sedation, duration of study drug infusion
and adverse effects.
Inadequate sedation Group D
(n= 55)
Group K
(n= 55)
P
value
Sedation failure 6 4
Onset of sedation time
(min)
15 ± 3.0 5 ± 1.54 0.010
Duration of study drug
infusion (min)
49 ± 14.81 52 ± 15.76 0.030
Adverse eﬀects
– Emesis 0 1 NS
– Agitation and dyspho-
ric reaction
0 2 NS
– Apnea 0 0
– Desaturation 6 5 NS
– Recovery time (min) 20 ± 4.65 21 ± 05.22 0.020
– Discharge time (min) 30 ± 18.35 50 ± 14.35 0.030
Data are expressed as mean ± SD, numbers (n).
P> 0.05 = non-signiﬁcant while P< 0.05 is signiﬁcant.
N/S = non-signiﬁcant.
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level of consciousness to baseline, and the ability to maintain
a patent airway.
2.1. Sample size
Prospective power analysis showed that a sample size of 55
patients per study group would have 80% power at the 10%
signiﬁcance level to detect the expected change.
The incidence of sedation failure was the primary endpoint
of the study. The alpha-error level was ﬁxed at 0.05.
3. Statistics
Analyses were done by IBM computer using statistical pro-
gram for social science (SPSS), description of quantitative vari-
ables as mean, SD and range description of qualitative variable
as numbers. The SPSS software used was version 20. The one-
sided test with a shifted hypothesis was used in the conﬁrma-
tory analysis. Analysis of variance for repeated measures was
performed on hemodynamic and respiratory parameters, with
compensation for post hoc comparisons using the Bonferroni
correction. Intergroup statistical analyses were performed
using the t-test, and non-parametric data were analyzed using
the X2-test. Statistical signiﬁcance was assumed at P< 0.05.
Results are presented as mean (SD).
The power of the study was calculated based on the
difference in the onset of sedation time between the two study
groups. Setting a signiﬁcance level of P= 0.05, it was
calculated that a group size of 55 patients allowed detection
of a difference between groups with a power of 80%.
4. Results
The patients’ demographics, presedation behavior score, and
the duration, type, and quality of MRI procedure were not
statistically different between groups (Table 2).Table 2 Patient characteristics, duration, and type of mag-
netic resonance imaging procedures.
Patient characteristic,
procedure
Group
D
(n= 55)
Group K
(n= 55)
Signiﬁcant
Age (yr) 5
± 1.67
5 ± 1.53 NS
Weight (kg) 14
± 4.03
14
± 4.73
NS
Sex (male/female) 33/22 26/29 NS
Presedation behavior score
– Undistressed (scores 1 & 2) 29 28
– Distressed (scores 3 & 4) 26 27
Duration of MRI (min) 35 ± 32 38
± 37.12
NS
Cranial MRI 32 30 NS
Extremity MRI 6 7 NS
Spine 7 9 NS
Thorax and abdomen 10 9 NS
Data are expressed as mean ± SD, numbers (n).
Group D (=dexmedetomidine); group K (=ketamine).
P> 0.05 = non-signiﬁcant and N/S = non signiﬁcant.Adequate sedation, as deﬁned by quality of the examina-
tion, was obtained in 49 children from group D and in 51
children from group K. Although, deep sedation (Ramsay
score of 5) was obtained with the dexmedetomidine or keta-
mine infusion before MRI examination, inadequate sedation
was observed in 6 children from group D and in 4 children
of group K during MRI. MRI examination was successfully
completed in all of these children with supplementary bolus
doses of propofol in group D and group K. In group K, the
onset of sedation was signiﬁcantly shorter than in group D
(P< 0.05), but the discharge time was longer in this group.
The level of consciousness was the same in both groups at
the time of discharge. The duration of drug infusion was not
different between groups (P> 0.05) (Table 3).
MAP, HR, and RR were not statistically different between
groups before sedation. MAP and HR decreased signiﬁcantly
from baseline during sedation in D group (P< 0.001), and
maintained or even increased in K group.
HR at 5, 15 min was signiﬁcantly more rapid in group K
than in group D, and MAP was higher in this group; however,
these differences were not clinically signiﬁcant. The RR was
statistically signiﬁcantly less in group K than in group D but
these differences were not clinically signiﬁcant. Bradycardia
was not observed in any child. Desaturation was observed in
6 children in group D and 5 children of group K, SpO2
decreased below 93% (average 89%) during MRI examina-
tion, usually after giving bolus of propofol. In these children,
oxygen desaturation was treated with chin lift and increasing
the oxygen supplementation via facemask. Side effects such
as nausea, vomiting or dysphoria were observed in 3 children
of group K, while it did not appear in group D during or after
sedation (Table 4).
5. Discussion
The main ﬁnding in the current randomized trial involving 110
ASA I–II physical status children (3–7 years) requiring seda-
tion during MRI can be summarized as follows: Both sedative
techniques (dexmedetomidine versus ketamine) can be used
Table 4 Hemodynamic and respiratory changes during study drug infusion.
Time (min) Baseline 5 15 30 45 P Value
MAP
Group K 90 ± 5.88 75 ± 7.53 74 ± 9.7 73 ± 8.35 76 ± 6.72§ 0.026
84 ± 10.6 92 ± 9.34 88 ± 8.42 95 ± 7.54 91 ± 0.53 0.029
*P value NS 0.024 0.014 0.026 0.021
HR
Group D 115 ± 11.69 92 ± 0.75 90 ± 0.86 94 ± 4.61 96 ± 4.3 0.038
Group K 109 ± 9.73 120 ± 8.59 119 ± 0.89 123 ± 5.57 119 ± 5.4 0.036
*P value NS 0.029 0.033 0.034 0.027
RR (respiratory rate)
Group D 26 ± 2.68 24 ± 3.72 24 ± 3.64 24 ± 3.83 24 ± 3.32 N/S
Group K 25 ± 0.59 22 ± 4.35 19 ± 4.86 17 ± 0.5 18 ± 1.7 0.022
*P value NS NS 0.018 0.022 0.021
SpO2
Group D 96 ± 3.76 98 ± 2.06 94 ± 5.47 96 ± 3.25 95 ± 2.79 N/S
Group K 95 ± 84.24 97 ± 3.43 95 ± 4.62 97 ± 2.93 96 ± 1.9 N/S
*P value NS NS NS NS NS
Data are expressed as mean ± SD, P> 0.05 = non-signiﬁcant (NS) comparing with baseline.
* P< 0.05 is signiﬁcant, comparing D group with K group.
266 A.M. Eldeek et al.safely in sedation for MRI. In group K, the onset of sedation
was signiﬁcantly shorter than in group D, but the recovery and
the discharge time were longer in this group. The level of con-
sciousness was the same in both groups at the time of dis-
charge. MAP and HR decreased signiﬁcantly from baseline
during sedation in group (D). Nausea, vomiting, and dyspho-
ria were observed in 3 children of group (K).
Sedation of children for MRI can be associated with difﬁ-
culty in obtaining deep sedation while maintaining hemody-
namic and respiratory stability [6]. The ideal pediatric
sedative drug should maintain patient’s ventilation, provide
hemodynamic stability, provide patient immobility, and allow
easy drug titration. It should also ensure rapid sedation induc-
tion time and recovery while providing minimal side effects
such as nausea, vomiting, dysphoria or pain [7]. Previous stud-
ies indicate that infusion of dexmedetomidine 0.1–0.7 lg/kg/h
provides effective sedation [8–10]. A sedation score between
2 and 4 was obtained with 0.5 lg/kg as loading and 0.25–
0.5 lg/kg/h. as infusion dose of dexmedetomidine [11]. In
our study, a dexmedetomidine loading dose of 1 lg/kg intra-
venously and infusion of 0.7 lg/kg/h were used. Adequate
sedation was obtained with dexmedetomidine in most of the
children and the others were effectively sedated with use of
bolus dose of propofol 0.5 mg/kg.
Arian and colleagues [12] reported a sedation induction
time of 25 min and recovery time of 34 min with dexmedeto-
midine in adults. The onset of sedation time and recovery time
was shorter in our study. This could be explained by the fact
that the subjects were children and that the duration of infu-
sion was shorter.
As regards the use of intravenous ketamine, reports of out-
patient ketamine use date back to the 1970s [13]. Dachs and
Innes [14] ﬁrst published on its use in the pediatric emergencies
in 1997 [14]. In their case series of 30 children given intra-
venous ketamine (1–2 mg/kg) all were adequately sedated
within two minutes. This consistency of effect was conﬁrmed
in our study, as we used a loading dose of l mg/kg intra-
venously followed by an infusion of 50–75 lg/kg/min for theduration of the procedure. Children in their study were dis-
charged at a mean time of 25 min after drug administration
compared with a mean time in our study at ketamine group
of almost 60 min.
There was prolonged recovery and discharge time in our
study, because our discharge criteria were more conservative
than those of Dachs and Innes [14], requiring that in addition
to a return to a normal conscious level and appropriate verbal-
ization, children needed to be free of nystagmus and ataxia.
Actually recovery agitation or emergence phenomena are
common with intravenous ketamine in the form of clumsiness
(evident as ataxic movements), dysphoric reaction hallucina-
tions or nightmares. A recent report has suggested that the
incidence of moderate to severe emergence phenomena associ-
ated with ketamine use is only l.6%, considerably less than the
previously described rate of up to 10% which is going with our
study as there are two patients had signs of emergence phe-
nomena [15].
Emesis is an important adverse event that can occur during
or after procedural sedation. It is considered one of the side
effects of ketamine, and actually, the rates of emesis in our
study are consistent with the incidence reported in other stud-
ies [16]. In Sherwin et al. [17], the incidence of emesis was 12%
in ketamine group. The dexmedetomidine group showed a
hemodynamic stability, in spite the contradictory results
related to its hemodynamic effects in some literature [18–20].
Hypotension and bradycardia have been reported particu-
larly with large bolus dosing regimens, in patients with cardiac
problems and in patients administered an initial dose in
<10 min [21,22]. In this study the initial dose of dexmedeto-
midine was administered over 10 min to minimize cardiovascu-
lar and respiratory depression related to initial dose, although
MAP and HR decreased after 15 min from the start of
dexmedetomidine infusion. This decreases because the patients
were not premeditated and the baseline values may have been
high and reﬂective of a time baseline value.
Because decreases in MAP and HR with dexmedetomidine
infusion were <20% of baseline and no bradycardia or
Sedation in children undergoing imaging comparative study 267hypotension occurred in any child, there decreases were con-
sidered clinically insigniﬁcant. As regards ketamine infusion,
there was hemodynamic stability, MAP and HR were main-
tained and even in the high side, and sometimes tachycardia
occurs but no clinical signiﬁcance clinically. Respiratory events
make up a large proportion (5.5%) of the complications of the
sedation in children. Some authors have reported that
dexmedetomidine does not affect RR, SpO2, and ETCO2 [2].
However, some respiratory complications have been reported
with large and rapid initial loading doses [19,21]. When a
dexmedetomidine initial was administered rapidly (2 min), it
caused irregular respiration, apnea, slight hypoxemia, and
hypercapnia.
In this current study, the clinically insigniﬁcant decrease in
RR during dexmedetomidine infusion may have been as a
result of high baseline values. For ketamine group no patient
had apnea or required the use of assisted ventilation. The rou-
tine use of anti-sialogogue could have reduced our incidence of
adverse respiratory events.
Lion and Mathios [23] reported that no relevant respiratory
effects of dexmedetomidine are known. Hemodynamic side-
effects such as low blood pressure and low heart rate are
common. A loading dose of 2–3 mg/kg over 10 min followed
by 1–2 mg/kg/h as an infusion for sedation maintenance is rec-
ommended. Several studies investigating dexmedetomidine for
sedation have been published. Mason and colleagues [24]
reported MRI procedures for 747 children and showed suc-
cessful imaging in 97.6%. Cardiovascular side-effects (brady-
cardia never exceeding a 20% range from standard values)
were seen in 16%. Oxygen saturation was always above 95%
[24]. In children with obstructive sleep apnea syndrome a com-
parison between dexmedetomidine and propofol for MRI
sleep induction revealed effective sedation without the need
for additional airway equipment in 88.5 versus 70% of scans
[25]. Some other investigations found no difference in success-
ful scanning between dexmedetomidine and propofol in 60
children between 1 and 7 years old but propofol showed
advantages in induction, recovery and discharge time. No oxy-
gen desaturation was seen in the dexmedetomidine-sedated
children [26]. Similar results were reported by Heard and col-
leagues [27], who compared a midazolam–dexmedetomidine
combination with propofol for sedation. The main ﬁnding in
Waleed et al. [28] in a randomized trial involving 60 ASA I
physical status children (4–10 years) requiring sedation during
dentistry procedure at dentistry outpatient clinic can be sum-
marized as follows: Both sedative techniques (dexmedeto-
midine versus propofol–midazolam) can be used safely in
outpatient dentistry clinic. Propofol–midazolam combination
can achieve rapid induction compared to dexmedetomidine
alone, reﬂected by shorter duration required to achieve RSS
P5. Dexmedetomidine had faster recovery compared to propo-
fol–midazolam combinations reﬂected by rapid restoration of
RSS of 2. Patients receiving dexmedetomidine requires less
analgesia supplementation in the early recovery period com-
pared to propofol–midazolam combination. Lubisch et al.
[29] published a retrospective study of children with autism
and other neurobehavioral disorders. Three hundred and ﬁf-
teen patients with a mean age of 3.9 years were sedated with
dexmedetomidine, most commonly for MRI, while 90% of
patients received concomitant midazolam. Seven patients
required intervention for cardiac events and one for a respira-
tory event. There were two episodes of recovery-related agita-tion; 98.7% of sedations were successfully completed [29]. In
the study of Tammam [30] was done on one-hundred and
sixty-two children with ASA physical I–II were enrolled in a
double-blind comparative study and assigned into three equal
groups for sedation. Group D, patients received IM
dexmedetomidine 3 ug/kg. Group K, patients received IM
ketamine 4 mg/kg. Group DK, patients received a combina-
tion of IM dexmedetomidine 1.5 ug/kg and ketamine 2 mg/
kg. The intramuscular mixture of dexmedetomidine and keta-
mine administration might avoid the adverse effects associated
with dexmedetomidine and ketamine; and might reduce the
need for titration, which is essential for IV sedation.
Thus, dexmedetomidine is suitable sedative agent and could
be an alternative to ketamine for MRI sedation in children.
Further studies with larger numbers of patients as structured
multicenter studies are required, and also to asses intramuscu-
lar and transnasal administration of dexmedetomidine for
MRI sedation.
In conclusion, dexmedetomidine provided adequate seda-
tion at l lg/kg loading and 0.7 lg/kg/h infusion doses in most
of children (aged between 3 and 7 years) without signiﬁcant
affection of hemodynamics, respiration, and with rapid
smooth recovery.
In comparison, ketamine provides adequate sedation at
l mg/kg intravenously as loading and 0.5–0.75 lg/kg/hr as
infusion doses, but with delayed discharge time than
dexmedetomidine and more side effects as emesis, dysphoric
reactions and sometimes with emergence phenomena.
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